CORPORATE SUMMARY

http://www.oneightyc.com
eric.walters@oneightyc.com

Delaware C Corp, registered in MA

Intellectual Property

Four issued US patents. US and foreign patent applications pending

Leadership

Eric G. Walters, Co-Founder, CEO and Board member:
Former EVP/CFO from inception of publicly-held medical device company that was sold for $1.5 billion.

Michael G. Fritz, Board member:
More than 20 years Big Four consulting and line management experience.

Advisors

Marcos Caro, Operations & QA/RA:
Leader in medical device operations and business enabling technologies with a proven track record in managing operations, supply-chain, engineering design, quality, regulatory and customer service.

Roy Coleman, Intellectual Property Counsel, Partner, Iandiorio, Teska & Coleman, LLP

Michael Drues, Ph.D., Regulatory Strategy: Worked for and consulted with leading medical device, pharmaceutical and biotechnology companies. He also works on a regular basis for the U.S. Food and Drug Administration

John Erickson, CEO, Product Resources: Experienced electrical engineer and technical manager with over 35 years' experience designing and building complex instruments in the medical device, industrial control, and instrumentation fields.

Theresa O'Keefe, Ph.D., Scientific Development: After 7 years in academic research, she spent more than 20 years in industry developing bio-therapeutic drugs (including inventing Entyvio) and medical devices; inventor on over 20 patents.

***Problem*: "High concern organisms" found on 5.4% of sampled reprocessed duodenoscopes. FDA target is <1% residual pathogens on duodenoscopes after reprocessing**.

***Solution*: *WAVE*Pulse™ can deliver the FDA target, thereby saving lives and millions of dollars in post-op and related costs traced to scope infections.**

***WAVE*Pulse™ Sterilization and Verification System:**

- Consistent sterilization achieved on duodenoscope elevator mechanism and lumens
- Create a universal standard of safety and verification across *all* reprocessed, temperature-sensitive medical devices.
- Completely non-toxic.

Our patent-pending sterilization reprocessor is designed to overcome infection risk from improperly cleaned temperature sensitive endoscopes. These devices can contain infectious residual biological debris. Unique combination of energies, temperature control and non-corrosive solvents result in consistent sterilization in a rapid cycle.

The patented (April 2019) verification capability of our system is designed to arm hospitals with currently unavailable information of every medically-critical bacterial and fungal pathogen that can remain on medical devices after reprocessing.

High-Growth Consumable Market:
High-margin, consumable proprietary solvents, integrated sterile wraps and single-use verification arrays are a key part of *WAVE*Pulse. Arrays have the added value of being universally applicable for other reprocessing systems, such as autoclaves and automatic endoscope reprocessors.

Total Addressable Markets:
Sterilization equipment and test strip markets are currently estimated to be $3.5B. More than 25 million endoscopic procedures, including colonoscopies, are performed each year.

Business and Operational Strategies:
Target end-markets include hospitals, surgical centers and medical device reprocessors.

Partner with endoscope manufacturers, medical device reprocessors and other strategic firms for product development, manufacturing, marketing, distribution and sales.

Manufacturing and fulfillment to be outsourced to appropriately certified facilities. Sold through multi-national strategics channel leveraging group purchasing organization relationships.

Competition:

	High Level Disenfection	Sterilization	Continuously Nontoxic	Processing time	System pricing
*WAVE*Pulse	✓	✓	✓	<60 mins	$$
Medivators - AER	✓	✗	✓	40 mins	$$
3M - EtO	✓	✓	✗	16 hrs	$$$
Steris - Peracetic acid	✓	✗	✗	3 hrs	$$
TSO_3	✗	✓	✗	45-60 mins	$$

Next-Gen *WAVE*Pulse Sterilization and Verification System Features:
Multi-Endoscope Modules
Integrated Sterile Wrap
Single-Use Verification Array

. Devices are currently under development, are not commercially available in the US, and Company statements have not yet been evaluated by the FDA.